Phase II study of an optimized 5-fluorouracil-oxaliplatin strategy (OPTIMOX2) with celecoxib in metastatic colorectal cancer: a GERCOR study.
暂无分享,去创建一个
C. Tournigand | F. Bidard | M. Hebbar | L. Mineur | A. de Gramont | T. André | C. Louvet | M. Flesch | M. Mabro | R. Fellague-Chebra | S. Postel Vinay
[1] C. Tournigand,et al. Chemotherapy-free intervals (CFI) in patients with metastatic colorectal cancer (MRC). , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[2] S. Barni,et al. Alternating versus continuous "FOLFIRI" in advanced colorectal cancer (ACC): A randomized "GISCAD" trial. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[3] L. Mineur,et al. OPTIMOX2, a large randomized phase II study of maintenance therapy or chemotherapy-free intervals (CFI) after FOLFOX in patients with metastatic colorectal cancer (MRC). A GERCOR study. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[4] C. Alexopoulos,et al. Continuous versus intermittent chemotherapy in metastatic colorectal cancer. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[5] M. Dong. OPTIMOX1:A Randomized Study of FOLFOX4 or FOLFOX7 with Oxaliplatin in A Stop-and-Go Fashion in Advanced Colorectal Cancer——A GERCOR Study , 2006 .
[6] C. Tournigand,et al. Oxaliplatin reintroduction in patients previously treated with leucovorin, fluorouracil and oxaliplatin for metastatic colorectal cancer. , 2004, Annals of oncology : official journal of the European Society for Medical Oncology.
[7] C. Tournigand,et al. FOLFIRI Followed by FOLFOX6 or the Reverse Sequence in Advanced Colorectal Cancer: A Randomized GERCOR Study , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[8] Daniel J Sargent,et al. A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[9] S. Fenwick,et al. Cyclooxygenase-2 expression in colorectal cancer liver metastases , 2004, Clinical & Experimental Metastasis.
[10] D. Kerr,et al. Comparison of intermittent and continuous palliative chemotherapy for advanced colorectal cancer: a multicentre randomised trial , 2003, The Lancet.
[11] Jilly F. Evans,et al. Inhibition of cyclooxygenase-2 by rofecoxib attenuates the growth and metastatic potential of colorectal carcinoma in mice. , 2003, Cancer research.
[12] Ahmedin Jemal,et al. Cancer Statistics, 2002 , 2002, CA: a cancer journal for clinicians.
[13] D. Kerr,et al. Continuous vs intermittant chemotherapy for advanced colorectal cancer: preliminary results of the MRC cr06b randomised trial , 2001 .
[14] C. Tournigand,et al. Evaluation of oxaliplatin dose intensity in bimonthly leucovorin and 48-hour 5-fluorouracil continuous infusion regimens (FOLFOX) in pretreated metastatic colorectal cancer. Oncology Multidisciplinary Research Group (GERCOR). , 2000, Annals of oncology : official journal of the European Society for Medical Oncology.
[15] Jilly F. Evans,et al. Chemoprevention of intestinal polyposis in the APCΔ716 mouse by rofecoxib, a specific cyclooxygenase-2 inhibitor , 2000, American Journal of Gastroenterology.
[16] C. Wilson,et al. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[17] B. Levin,et al. The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis. , 2000, The New England journal of medicine.
[18] K. Seibert,et al. Antiangiogenic and antitumor activities of cyclooxygenase-2 inhibitors. , 2000, Cancer research.
[19] V. Steele,et al. Chemoprevention of colon cancer by specific cyclooxygenase-2 inhibitor, celecoxib, administered during different stages of carcinogenesis. , 2000, Cancer research.
[20] W. Ray,et al. Use of nonsteroidal anti-inflammatory drugs and incidence of colorectal cancer: a population-based study. , 1999, Archives of internal medicine.
[21] J. Morrow,et al. Inhibition of human colon cancer cell growth by selective inhibition of cyclooxygenase-2. , 1997, The Journal of clinical investigation.
[22] Bruno C. Hancock,et al. Suppression of Intestinal Polyposis in Apc Δ716 Knockout Mice by Inhibition of Cyclooxygenase 2 (COX-2) , 1996, Cell.
[23] D. Khayat,et al. Chimiothérapie des cancers colorectaux , 1996 .
[24] M. Kondo,et al. Expression of cyclooxygenase-1 and -2 in human colorectal cancer. , 1995, Cancer research.
[25] S. Piantadosi,et al. Treatment of colonic and rectal adenomas with sulindac in familial adenomatous polyposis. , 1993, The New England journal of medicine.
[26] N. Dubrawsky. Cancer statistics , 1989, CA: a cancer journal for clinicians.